logo

CIPLA vs WOCKPHARMA: Stock Comparison

CIPLA vs WOCKHARDTUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

CIPLA is the larger company by market capitalisation. CIPLA shows a lower P/E, a higher ROE and a higher dividend yield, while WOCKHARDT shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CIPLA leads 11; WOCKPHARMA leads 2 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CIPLAWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹1.07 L Cr
₹30,126 Cr
P/E RatioCIPLA has the lower reading
31.87x ✓
73.66x
P/B RatioCIPLA has the lower reading
3.12x ✓
6.1x
EPSCIPLA has the higher reading
₹41.7 ✓
₹6.52
Book ValueContext only
₹426.25
₹325
Dividend YieldCIPLA has the higher reading
0.98% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CIPLA is the larger company
₹1.07 L Cr vs ₹30,126 Cr
P/E Ratio
CIPLA has a lower P/E
31.87x vs 73.66x
P/B Ratio
CIPLA has a lower P/B
3.12x vs 6.1x
EPS
CIPLA has higher earnings per share
₹41.7 vs ₹6.52
Dividend Yield
CIPLA has a higher dividend yield
0.98% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -2.1%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
CIPLA has stronger quarterly sales growth
8.84% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAWOCKPHARMA
Live Price₹1,330.9₹1,855.5
Day Change1.29%-1.16%
Volume6.39 L4.57 L
52-Week High₹1,673₹2,422.3
52-Week Low₹1,165.7₹1,086.7
Distance from 52W High-20.45%-23.4%

Valuation

MetricCIPLAWOCKPHARMA
Market Cap₹1.07 L Cr₹30,126 Cr
P/E Ratio31.87x73.66x
P/B Ratio3.12x6.1x
EPS₹41.7₹6.52
Book Value₹426.25₹325
Dividend Yield0.98%0%

Growth

MetricCIPLAWOCKPHARMA
Revenue Growth (TTM YoY)-2.1%26%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth8.84%0%
Qtr Profit Growth44.8%0%

Profitability & Leverage

MetricCIPLAWOCKPHARMA
ROE11.19%3.77%
ROCE11.58%5.44%
Net Margin13.96%3.3%
Operating Margin18.74%13.37%
Debt to Equity0.01x0.4x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCIPLAWOCKPHARMA
Promoter Holding9.17%49.08%
FII Holding20.21%▼ 2.35 pp7.22%▲ 0.13 pp
DII Holding34.63%▲ 2.66 pp9.24%▼ 1.72 pp
Public Holding15.94%▼ 0.31 pp34.44%▲ 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CIPLA and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.